You mean the enrollment speed of CD17 (25 patients in ~ 2 months) could slow down CD16?

I assume it is much more easier to get the consent of critical ill patients (relatives sign) to join our critical trial than in the severe population.

I guess this break of CD17 is rather due to costs, competition with other drug trials in severe population, highest chance of success with CD16, resource concentration of Albert Einstein and BIOMM, ...

Or it is more strategic. Since the CD17 vials are already cleared by Brazil customs and ready for use, it could speed up a long hauler or cancer trial in Brazil.

I have to say I am pleased that Nader starts focusing in Brazil for once. Could be the right direction in the rough sea we are currently sailing. Get those 40 trial sites up and running!